
a
Relative Expression
80
60
40
20
3
2
1
0
*
NP69
C666-1
NP460
miR-449b
b
Cell Viability (%)
100
80
60
40
20
0
***
*
NP69
C666-1
NP460
0
5
10
15
Cisplatin (μg/mL)
c
Fold Change in Caspase-3 Activity
60
40
20
0
*
***
NP69
C666-1
NP460
3.125
6.250
12.500
Cisplatin (μg/mL)
d
NP69
C666-1
NP460
αpP44/42 (T202/Y204)
Phospho-ERK1/2 (T202/Y204); 42/44 kDa
αtotal-p44/42
total ERK1/2; 42/44 kDa
αtotal-p38
total p38; 43 kDa
αβ-actin
β-actin; 42 kDa
αpSAPK/JNK (T183/Y185)
Phospho-SAPK/JNK (T183/Y185); 46/54 kDa
αtotal-SAPK/JNK
total SAPK/JNK; 46/54 kDa
αβ-actin
β-actin; 42 kDa
e
NP69
MiRNA CTL
Pre-miR 449b
αpP44/42 (T202/Y204)
Phospho-ERK1/2 (T202/Y204); 42/44 kDa
αtotal-p44/42
total ERK1/2; 42/44 kDa
αtotal-p38
total p38; 43 kDa
αβ-actin
β-actin; 42 kDa
αpSAPK/JNK (T183/Y185)
Phospho-SAPK/JNK (T183/Y185); 46/54Da
αtotal-SAPK/JNK
total SAPK/JNK; 46/54 kDa
αβ-actin
β-actin; 42 kDa
f
NP69
C666-1
NP460
αpPTEN (S380)
pPTEN (S380); 54 kDa
αtotal-PTEN
total-PTEN; 54 kDa
αβ-actin
β-actin; 42 kDa
αpAKT (S473)
pAKT (S473); 60 kDa
αpan-AKT
pan-AKT; 60 kDa
αβ-actin
β-actin; 42 kDa
g
NP69
Cell Viability (%)
100
80
60
40
20
0
n.s
n.s
***
*
miR control
pre-miR 449b
MK2206 0.1μM
MK2206 1μM
CDDP 1.5 μg/mL
CDDP + MK2206 0.1μM
CDDP + MK2206 1μM

Figure S1.